Placebo for ribavirin

DRUG5 trials

Sponsors

Conatus Pharmaceuticals Inc., AbbVie (prior sponsor, Abbott), AbbVie

Conditions

Chronic Hepatitis C InfectionHepatitis C

Phase 2

CTS-1027 in Interferon-Naive Hepatitis C Patients

CompletedNCT00925990

Conatus Pharmaceuticals Inc.Hepatitis C

Start: 2009-06-30End: 2010-07-31Updated: 2012-03-27

Phase 3

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

CompletedNCT01715415

AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Infection

Start: 2012-11-30End: 2014-10-31Updated: 2021-08-02

A Study to Evaluate Chronic Hepatitis C Infection

CompletedNCT01716585

AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Infection

Start: 2012-11-30End: 2014-10-31Updated: 2021-07-12

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection

CompletedNCT01767116

AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Infection

Start: 2012-12-31End: 2014-08-31Updated: 2021-07-12

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection

CompletedNCT01833533

AbbVieChronic Hepatitis C Infection

Start: 2013-03-31End: 2014-09-30Updated: 2021-07-12

Related Papers

Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen.

2018-01-0139 citations

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

New England Journal of Medicine2014-05-04690 citations

Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

New England Journal of Medicine2014-04-11899 citations

Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

New England Journal of Medicine2014-04-10514 citations